A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood

References

• Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. 2016. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer. 4:72.
   Web of Science ®Google Scholar
• An G. 2020. Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds. J Clin Pharmacol. 60(2):149–63.
   PubMed Web of Science ®Google Scholar
• Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al. 2020. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med. 383(23):2207–18.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. 2017. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 127(8):2930–40.
   PubMed Web of Science ®Google Scholar
• Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, et al. 2011. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Clin Cancer Res. 17(19):6329–37.
   PubMed Web of Science ®Google Scholar
• Badawi M, Coss CC, Phelps MA. 2019. Letter to the editor: exposure-response or clearance-response relationship in immune checkpoint therapy?-A comment on ‘correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer’ by Basak et al. Eur J Cancer. 114:25–26.
   PubMed Web of Science ®Google Scholar
• Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. 2017. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol. 6(1):58–66.
   PubMedGoogle Scholar
• Ballman KV. 2015. Biomarker: predictive or Prognostic? J Clin Oncol. 33(33):3968–71.
   PubMed Web of Science ®Google Scholar
• Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. 2018. Cancer-associated cachexia. Nat Rev Dis Primers. 4:17105.
   PubMed Web of Science ®Google Scholar
• Bardal SK, Waechter JE, Martin DS. 2011. Chapter2 - pharmacokinetics. Philadelphia: Elsevier.
   Google Scholar
• Basak EA, Koolen SLW, Hurkmans DP, Schreurs MWJ, Bins S, Oomen-de Hoop E, Wijkhuijs AJM, Besten ID, Sleijfer S, Debets R, et al. 2019. Correlation between nivolumab exposure and treatment outcomes in non–small-cell lung cancer. Eur J Cancer. 109:12–20.
   PubMed Web of Science ®Google Scholar
• Bellesoeur A, Ollier E, Allard M, Hirsch L, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tiako M, Khoudour N, Chapron J, et al. 2019. Is there an exposure–response relationship for nivolumab in real-world NSCLC patients? Cancers (Basel). 11(11):1784.
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D. 1998. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 9(9):995–1001.
   PubMed Web of Science ®Google Scholar
• Chatelut E, Hendrikx J, Martin J, Ciccolini J, Moes D. 2021. Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. Pharmacol Res Perspect. 9(2):e00757.
   PubMed Web of Science ®Google Scholar
• Curti BD, Koguchi Y, Leidner RS, Rolig AS, Sturgill ER, Sun Z, Wu Y, Rajamanickam V, Bernard B, Hilgart-Martiszus I, et al. 2021. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. J Immunother Cancer. 9(4):e002371.
   PubMed Web of Science ®Google Scholar
• Dai HI, Vugmeyster Y, Mangal N. 2020. Characterizing exposure-response relationship for therapeutic monoclonal antibodies in immuno-oncology and beyond: challenges, perspectives, and prospects. Clin Pharmacol Ther. 108(6):1156–70.
   Web of Science ®Google Scholar
• Dalloneau E, Baroukh N, Mavridis K, Maillet A, Gueugnon F, Courty Y, Petit A, Kryza T, Del Rio M, Guyetant S, et al. 2016. Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis. Oncotarget. 7(34):54415–29.
   PubMedGoogle Scholar
• Dumont FJ. 2002. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond. Expert Rev Anticancer Ther. 2(1):23–35.
   PubMedGoogle Scholar
• Feng Y, Masson E, Dai D, Parker SM, Berman D, Roy A. 2014. Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. Br J Clin Pharmacol. 78(1):106–17.
   PubMed Web of Science ®Google Scholar
• Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. 2013. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res. 19(14):3977–86.
   PubMed Web of Science ®Google Scholar
• Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT. 2016. Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab. 24(5):672–84.
   PubMed Web of Science ®Google Scholar
• Fracasso PM, Burris H 3rd, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, et al. 2007. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res. 13(3):986–93.
   PubMed Web of Science ®Google Scholar
• Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, et al. 2016. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 167(2):397–404 e9.
   PubMed Web of Science ®Google Scholar
• Garcia-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, Stintzing S. 2019. Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors. Front Oncol. 9:849.
   PubMed Web of Science ®Google Scholar
• Greten FR, Grivennikov SI. 2019. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 51(1):27–41.
   PubMed Web of Science ®Google Scholar
• Hale G, Rebello P, Brettman LR, Fegan C, Kennedy B, Kimby E, Leach M, Lundin J, Mellstedt H, Moreton P, et al. 2004. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood. 104(4):948–55.
   PubMed Web of Science ®Google Scholar
• Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, et al. 2017. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 545(7652):60–65.
   PubMed Web of Science ®Google Scholar
• Hurkmans DP, Basak EA, van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM, Bins S, Hoop E-D, Debets R, Joerger M, et al. 2019. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J ImmunoTher Cancer. 7(1). doi:10.1186/s40425-019-0669-y.
   Google Scholar
• Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM. 2009. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 128(2):260–70.
   PubMed Web of Science ®Google Scholar
• Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, Morishima Y, Murate T, Kasai M, Uike N, et al. 2002. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol. 13(6):928–43.
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Koguchi Y, Yokoyama K, Hamada A, Yonezawa A, Piening BD, Tran E, Fox BA, Redmond WL, Shimada T. 2022. A rapid and universal liquid chromatograph-mass spectrometrybased platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics. Analyst (Lond). 147:4275–84. In Press. doi:10.1039/D2AN01032A.
   Web of Science ®Google Scholar
• Iwamoto N, Shimada T. 2018. Recent advances in mass spectrometry-based approaches for proteomics and biologics: great contribution for developing therapeutic antibodies. Pharmacol Ther. 185:147–54.
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Shimada T. 2022. Structure-indicated LC-MS/MS bioanalysis of therapeutic antibodies. Methods Mol Biol. 231:3187–205.
   Google Scholar
• Iwamoto N, Shimada T, Umino Y, Aoki C, Aoki Y, Sato TA, Hamada A, Nakagama H. 2014. Selective detection of complementarity-determining regions of monoclonal antibody by limiting protease access to the substrate: nano-surface and molecular-orientation limited proteolysis. Analyst (Lond). 139(3):576–80.
   Web of Science ®Google Scholar
• Jiang T, Zhou C, Ren S. 2016. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 5(6):e1163462.
   PubMed Web of Science ®Google Scholar
• Koguchi Y, Hoen HM, Bambina SA, Rynning MD, Fuerstenberg RK, Curti BD, Urba WJ, Milburn C, Bahjat FR, Korman AJ, et al. 2015. Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab. Cancer Res. 75(23):5084–92.
   PubMed Web of Science ®Google Scholar
• Koguchi Y, Iwamoto N, Shimada T, Chang SC, Cha J, Curti BD, Urba WJ, Piening BD, Redmond WL. 2021. Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab. J Immunother Cancer. 9(10).
   Web of Science ®Google Scholar
• Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. 2010. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 116(7):1767–75.
   PubMed Web of Science ®Google Scholar
• Laws LH, Parker CE, Cherala G, Koguchi Y, Waisman A, Slifka MK, Oberbarnscheidt MH, Obhrai JS, Yeung MY, Riella LV. 2016. Inflammation causes resistance to anti-CD20-mediated B cell depletion. Am J Transplant. 16(11):3139–49.
   PubMed Web of Science ®Google Scholar
• Ledford H, Else H, Warren M. 2018. Cancer immunologists scoop medicine Nobel prize. Nature. 562(7725):20–21.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. 2015. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 372(26):2509–20.
   PubMed Web of Science ®Google Scholar
• Levy J, Barnett EV, MacDonald NS, Klinenberg JR. 1970. Altered immunoglobulin metabolism in systemic lupus erythematosus and rheumatoid arthritis. J Clin Invest. 49(4):708–15.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Drake CG. 2011. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 17(22):6958–62.
   PubMed Web of Science ®Google Scholar
• Liu L. 2018. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 9(1):15–32.
   PubMed Web of Science ®Google Scholar
• Liu B, Hu X, Feng K, Gao R, Xue Z, Zhang S, Zhang Y, Corse E, Hu Y, Han W, et al. 2022. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat Cancer. 3(1):108–21.
   PubMedGoogle Scholar
• Liu X, Ye L, Bai Y, Mojidi H, Simister NE, Zhu X. 2008. Activation of the JAK/STAT-1 signaling pathway by IFN-gamma can down-regulate functional expression of the MHC class I-related neonatal Fc receptor for IgG. J Immunol. 181(1):449–63.
   PubMed Web of Science ®Google Scholar
• Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, Blumenthal GM, Turner DC, Li C, Ahamadi M, et al. 2017. Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn. 44(5):403–14.
   PubMed Web of Science ®Google Scholar
• Merry C, Flexner CW. 2008. Pharmacology of antiretroviral drugs. In: Global HIV/AIDS medicine. Philadelphia: Elsevier; pp. 171–79.
   Google Scholar
• Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P, Brettman LR, Reif S, Bonate PL. 2007. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol. 64(3):278–91.
   PubMed Web of Science ®Google Scholar
• Navani V, Graves MC, Marchett GC, Mandaliya H, Bowden NA, van der Westhuizen A. 2021. Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers. Pharmacol Res Perspect. 9(4):e00808.
   PubMed Web of Science ®Google Scholar
• Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. 2013. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res. 1(4):229–34.
   PubMed Web of Science ®Google Scholar
• Oude Munnink TH, Henstra MJ, Segerink LI, Movig KL, Brummelhuis-Visser P. 2016. Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: translating TNF-alpha experience to oncology. Clin Pharmacol Ther. 99(4):419–31.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, et al. 2019. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 17(9):1655–68 e3.
   PubMed Web of Science ®Google Scholar
• Robert C. 2020. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 11(1):3801.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Dudley ME. 2009. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 21(2):233–40.
   PubMed Web of Science ®Google Scholar
• Sanghavi K, Zhang J, Zhao X, Feng Y, Statkevich P, Sheng J, Roy A, Vezina HE. 2020. Population pharmacokinetics of ipilimumab in combination with nivolumab in patients with advanced solid tumors. CPT Pharmacometrics Syst Pharmacol. 9(1):29–39.
   PubMedGoogle Scholar
• Schumacher TN, Schreiber RD. 2015. Neoantigens in cancer immunotherapy. Science. 348(6230):69–74.
   PubMed Web of Science ®Google Scholar
• Shmais M, Regueiro M, Hashash JG. 2021. Proactive versus reactive therapeutic drug monitoring: why, when, and how? Inflammatory Intestinal Dis. 7:1–9.
   Google Scholar
• Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. 2014. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 371(23):2189–99.
   PubMed Web of Science ®Google Scholar
• Stroh M, Winter H, Marchand M, Claret L, Eppler S, Ruppel J, Abidoye O, Teng SL, Lin WT, Dayog S, et al. 2017. Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin Pharmacol Ther. 102(2):305–12.
   PubMed Web of Science ®Google Scholar
• Tighe PJ, Ryder RR, Todd I, Fairclough LC. 2015. ELISA in the multiplex era: potentials and pitfalls. Proteomics Clin Appl. 9(3–4):406–22.
   PubMed Web of Science ®Google Scholar
• Tobinai K, Igarashi T, Itoh K, Kobayashi Y, Taniwaki M, Ogura M, Kinoshita T, Hotta T, Aikawa K, Tsushita K, et al. 2004. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol. 15(5):821–30.
   PubMed Web of Science ®Google Scholar
• Todoroki K, Mizuno H, Sugiyama E, Toyo’Oka T. 2020. Bioanalytical methods for therapeutic monoclonal antibodies and antibody-drug conjugates: a review of recent advances and future perspectives. J Pharm Biomed Anal. 179:112991.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. 2012. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 366(26):2443–54.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515(7528):568–71.
   PubMed Web of Science ®Google Scholar
• Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW, et al. 2018. Pembrolizumab exposure–response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res. 24(23):5841–49.
   PubMed Web of Science ®Google Scholar
• Wang E, Kang D, Bae KS, Marshall MA, Pavlov D, Parivar K. 2014. Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma. J Clin Pharmacol. 54(10):1108–16.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. 2018. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8(9):1069–86.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O’Brien SM, et al. 2011. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 117(1):116–24.
   PubMed Web of Science ®Google Scholar
• Wilkins JJ, Brockhaus B, Dai H, Vugmeyster Y, White JT, Brar S, Bello CL, Neuteboom B, Wade JR, Girard P, et al. 2019. Time-varying clearance and impact of disease state on the pharmacokinetics of avelumab in Merkel cell carcinoma and urothelial carcinoma. CPT Pharmacometrics Syst Pharmacol. 8(6):415–27.
   PubMedGoogle Scholar
• Wochner RD. 1970. Hypercatabolism of normal IgG; an unexplained immunoglobulin abnormality in the connective tissue diseases. J Clin Invest. 49(3):454–64.
   PubMedGoogle Scholar